Bristol-Myers Squibb (NYSE:BMY) was downgraded by analysts at Vetr from a "buy" rating to a "hold" rating in a note issued to investors on Friday. They currently have a $59.70 target price on the biopharmaceutical company’s stock. Vetr‘s price target suggests a potential downside of 2.07% from the stock’s previous close.
Other equities research analysts also recently issued reports about the company. Jefferies Group restated a "buy" rating and set a $72.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Cowen restated a "hold" rating and set a $65.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Piper Jaffray Companies restated a "hold" rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Hilliard Lyons downgraded Bristol-Myers Squibb from a "long-term buy" rating to a "neutral" rating and set a $65.00 price objective on the stock. in a research report on Tuesday, September 12th. Finally, Credit Suisse Group reiterated a "hold" rating on shares of Bristol-Myers Squibb in a report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of "Hold" and a consensus target price of $64.42.
Bristol-Myers Squibb traded down $0.54 during trading hours on Friday, hitting $60.96. The company had a trading volume of 5,470,719 shares, compared to its average volume of 8,303,741. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $100,166.05, a P/E ratio of 24.00, a P/E/G ratio of 2.32 and a beta of 1.18. Bristol-Myers Squibb has a 12 month low of $46.01 and a 12 month high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter in the prior year, the firm posted $0.77 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 6.7% on a year-over-year basis. equities research analysts predict that Bristol-Myers Squibb will post 2.99 earnings per share for the current year.
In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Theodore R. Samuels II acquired 4,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the acquisition, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of BMY. Blue Chip Partners Inc. raised its position in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the period. Jackson Grant Investment Advisers Inc. raised its position in Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 15 shares during the period. Chilton ...
(All Rights Reserved)